Drug Profile

ACD 440

Alternative Names: ACD-440; TRPV1 receptor antagonist - AlzeCure; VR1 antagonist - AlzeCure; VR1/ACD440

Latest Information Update: 13 Oct 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Developer AlzeCure
Class Analgesics; Benzimidazoles; Non-opioid analgesics; Small molecules
Mechanism of Action TRPV1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Neuropathic pain

Most Recent Events

12 Oct 2023 Efficacy and adverse event data from a phase II trial in Neuropathic pain in Sweden released by AlzeCure
20 Sep 2023 Efficacy from a phase II trial in Neuropathic pain released by AlzeCure Pharma
24 May 2023 Adverse events from a phase II trial in Neuropathic pain released by AlzeCure Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com